Shinya Mizutani

Dr. Shinya Mizutani

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Open Veterinary Journal
Verified
Journal Article
Open access
YGYoshimichi Goda
Yoshimichi Goda
SMShinya Mizutani
Shinya Mizutani
NANatsuki Akashi
Natsuki Akashi
TKTeppei Kanda
Teppei Kanda
KKKenji Kutara
Kenji Kutara
TATaketoshi Asanuma
Taketoshi Asanuma
Background: Lung tumors in dogs, significantly primary paragangliomas, are rare and have not been reported. This report describes a dog with a lung tumor diagnosed as a primary paraganglioma. Case Description: A 12-year-old spayed French bulldog presented with a left-sided pulmonary mass. The dog was in good general condition and had no clinical symptoms. Computed tomography (CT) revealed a pulmonary mass near the bifurcation of the posterior lobe bronchus of the left lung. The mass showed a strong contrast enhancement effect that was subsequently attenuated. The dog underwent Surgery to remove the mass from the left lung. Abnormal hypertension was observed during surgery, and hypertensive crisis was suspected. Based on the histopathology and preoperative and postoperative urinary metanephrine and normetanephrine levels, the dog was diagnosed with primary paraganglioma of the lung. Although the CT scan showed findings suggestive of the development of a neuroendocrine tumor, it was difficult to suspect the development of a paraganglioma. Conclusion: The possibility of catecholamine-producing tumors should be considered when we encounter a lung tumor with no clinical symptoms and a neuroendocrine tumor like contrast enhancement pattern on CT scan.

1 January 2025 in Journal of Veterinary Medical Science
Verified
Journal Article
Open access
PDF file
SMShinya Mizutani
Shinya Mizutani
YMYuko Mizutani
Yuko Mizutani
YGYoshimichi Goda
Yoshimichi Goda
HSHiroyuki Satoh
Hiroyuki Satoh
TATaketoshi Asanuma
Taketoshi Asanuma
STShidow Torisu
Shidow Torisu
An 11-year-old male French bulldog presented with incidental cystic lesions by the pulmonary CT. CT revealed two cysts in the right caudal lobe of the lung that were suspicious for emphysematous lesions. These cysts were divided into an air layer and a soft tissue-like layer. Dynamic computed tomography (DCT) of cysts revealed undulating motion in the soft tissue-like layer. The dog’s rearing environment included brackish water, and it was evident that the dog had been eating brackish water crabs from the river. The dog was diagnosed with paragonimiasis. This DCT imaging revealed movement of live worms inside the cysts. This study is the first report that DCT may be useful for differentiating paragonimiasis from other pulmonary lesions.

1 August 2025 in Animals
Verified
Journal Article
Open access
PDF file
AOAkihiro Ohnishi
Akihiro Ohnishi
STSoichirou Takeda
Soichirou Takeda
YOYoshiki Okada
Yoshiki Okada
MTManami Tokoro
Manami Tokoro
SKSaki Kageyama
Saki Kageyama
TATaketoshi Asanuma
Taketoshi Asanuma
Radiation-induced keratoconjunctivitis sicca (KCS) is a significant late complication in dogs receiving radiation therapy for intranasal tumors, particularly with hypofractionated intensity-modulated radiation therapy (IMRT). This retrospective case-control study was performed to identify anatomical and dosimetric risk factors for KCS in 15 canine patients treated with IMRT delivered in 4–6 weekly fractions of 8 Gy. Orbital structures were retrospectively contoured, and dose–volume metrics (D50) were calculated. Receiver operating characteristic (ROC) curve analysis and odds ratios were used to evaluate the associations between radiation dose and KCS development. Six dogs (33%) developed KCS within three months post-treatment. Statistically significant dose differences were observed between affected and unaffected eyes for the eyeball, cornea, and retina. ROC analyses identified dose thresholds predictive of KCS: 13.8 Gy (eyeball), 14.9 Gy (cornea), and 17.0 Gy (retina), with the retina showing the highest odds ratio (28.33). To ensure clinical relevance, KCS was diagnosed based on decreased tear production combined with corneal damage to ensure clinical relevance. This study proposes dose thresholds for ocular structures that may guide treatment planning and reduce the risk of KCS in canine patients undergoing IMRT. Further prospective studies are warranted to validate these thresholds and explore mitigation strategies for high-risk cases.

22 August 2023 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
YMYuko Mizutani
Yuko Mizutani
YIYoshiyuki Inoue
Yoshiyuki Inoue
YGYoshimichi Goda
Yoshimichi Goda
SMShinya Mizutani
Shinya Mizutani
TATaketoshi Asanuma
Taketoshi Asanuma
HShiroyuki satoh
hiroyuki satoh
Of intracranial tumors, primary central nervous system lymphoma (PCNSL) is rare in dogs. Herein, we describe our experience with two dogs (a 3-year-old intact female toy poodle and a 5-year-old spayed female toy poodle) that developed neurological symptoms. Magnetic resonance imaging (MRI) revealed intracranial disseminated lesions. Cerebrospinal fluid (CSF) examination revealed pleocytosis and B-cell monoclonal proliferation in both cases. PCNSL or secondary central nervous system lymphoma (SCNSL) was diagnosed on the basis of MRI findings and CSF examinations. Nimustine (ACNU) is a nitrosourea alkylating agent, a class of drugs that includes lomustine. Nimustine is mainly used to treat human intracranial neoplasia because of its high permeability across the blood-brain barrier. The dogs in this study were treated with combined chemotherapy comprising nimustine and prednisolone, which achieved complete or nearly complete remission of neurological symptoms and long-term survival (>2583 days and 1218 days), but with problematic adverse effects. We determined that the dose of nimustine for canine PCNSL or SCNSL with intravenous infusion was 25–30 mg/m2 every 3–4 weeks for a total of four times; however, the data were insufficient to determine the optimal regimen.

20 June 2026 in Veterinary Sciences
Verified
Journal Article
Open access
PDF file
AOAkihiro Ohnishi
Akihiro Ohnishi
YMYuko Mizutani
Yuko Mizutani
SKSaki Kageyama
Saki Kageyama
SMShinya Mizutani
Shinya Mizutani
TATaketoshi Asanuma
Taketoshi Asanuma
We described tumor response and survival in dogs with modified Adams stage 4 intranasal tumors treated with once-weekly hypofractionated radiation therapy (RT) combined with the radiosensitizer α-sulfoquinovosyl-acylpropanediol (SQAP), and compared linear and volumetric response assessments. Twenty dogs treated with intensity-modulated RT (8 Gy per fraction, once weekly) and concurrent SQAP were included in this retrospective case series. Tumor response was assessed using RECIST-like linear measurements and volumetric analysis on contrast-enhanced computed tomography. Overall survival (OS) was estimated using Kaplan–Meier analysis. Of the 20 dogs, 4 were classified as stage 4a and 16 as stage 4b. The best RECIST-like responses were complete response (CR) in 5 dogs, partial response (PR) in 12, and stable disease (SD) in 4. Volumetric responses were CR in 5 dogs, PR in 11, and SD in 5. No cases demonstrated progressive disease as the best response. The median OS for all dogs was 342 days (95% confidence interval [CI], 206–419 days). Censoring one non-tumor-related death yielded a median OS of 356 days (95% CI, 231–419 days). Exploratory analysis revealed median OS of 393 and 297 days for stage 4a and 4b dogs, respectively. Volumetric assessment appeared more sensitive for detecting tumor regrowth in selected cases. Dermatologic adverse events were limited to alopecia within the radiation field, and no complete vision loss was observed. Seizure activity was documented in eight dogs. In conclusion, once-weekly hypofractionated intensity-modulated RT combined with concurrent SQAP was associated with clinically meaningful survival outcomes in dogs with advanced intranasal tumors. However, because no radiotherapy-alone control group was available, the independent contribution of SQAP to these outcomes could not be determined.

1 March 2025
Verified
Journal Article
Closed access
SMShinya Mizutani
Shinya Mizutani
YMYuko Mizutani
Yuko Mizutani
YGYoshimichi Goda
Yoshimichi Goda
TATaketoshi Asanuma
Taketoshi Asanuma
STShidow Torisu
Shidow Torisu